Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Accured Expenses: 2017-2025

Historic Change in Accured Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $1.3 million.

  • Aclaris Therapeutics' Change in Accured Expenses rose 213.00% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 122.53%. This contributed to the annual value of -$3.9 million for FY2024, which is 132.87% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Change in Accured Expenses stood at $1.3 million for Q3 2025, which was up 224.56% from $399,000 recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Change in Accured Expenses peaked at $11.6 million during Q4 2024, and registered a low of -$12.9 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was $399,000 (2025), whereas its average is -$118,091.
  • In the last 5 years, Aclaris Therapeutics' Change in Accured Expenses skyrocketed by 928.49% in 2023 and then tumbled by 1,012.67% in 2024.
  • Aclaris Therapeutics' Change in Accured Expenses (Quarterly) stood at $2.5 million in 2021, then slumped by 126.81% to -$681,000 in 2022, then soared by 928.49% to $5.6 million in 2023, then spiked by 105.10% to $11.6 million in 2024, then spiked by 213.00% to $1.3 million in 2025.
  • Its Change in Accured Expenses stands at $1.3 million for Q3 2025, versus $399,000 for Q2 2025 and -$11.0 million for Q1 2025.